Related Papers
A self-aggregating peptide: Implications for the development of thermostable vaccine candidates
Luis Vaca
Background: The use of biomaterials has been expanded to improve the characteristics of vaccines. Recently we have identified that the peptide PH(1-110) from polyhedrin self-aggregates and incorporates foreign proteins to form particles. We have proposed that this peptide can be used as an antigen carrying system for vaccines. However, the immune response generated by the antigen fused to the peptide has not been fully characterized. In addition, the adjuvant effect and thermostability of the particles has not been evaluated. Results: In the present study we demonstrate the use of a system developed to generate nano and microparticles carrying as a fusion protein peptides or proteins of interest to be used as vaccines. These particles are purified easily by centrifugation. Immunization of animals with the particles in the absence of adjuvant result in a robust and long-lasting immune response. Proteins contained inside the particles are maintained for over one year at ambient temper...
Journal of drug delivery
An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines
2011 •
Manoli Igartua
The development of synthetic peptide-based vaccines has many advantages in comparison with vaccines based on live attenuated organisms, inactivated or killed organism, or toxins. Peptide-based vaccines cannot revert to a virulent form, allow a better conservation, and are produced more easily and safely. However, they generate a weaker immune response than other vaccines, and the inclusion of adjuvants and/or the use of vaccine delivery systems is almost always needed. Among vaccine delivery systems, micro- and nanoparticulated ones are attractive, because their particulate nature can increase cross-presentation of the peptide. In addition, they can be passively or actively targeted to antigen presenting cells. Furthermore, particulate adjuvants are able to directly activate innate immune system in vivo. Here, we summarize micro- and nanoparticulated vaccine delivery systems used in the field of synthetic peptide-based vaccines as well as strategies to increase their immunogenicity.
International Journal of Pharmacy and Pharmaceutical Sciences
An Overview of Recombinant Vaccine Technology, Adjuvants and Vaccine Delivery Methods
2016 •
shuaibu umar
Development of an effective vaccine is of paramount important in disease prevention and control. As such, recombinant technology can serve as a gateway for the development of safe and effective vaccines that can be delivered effectively with an appropriate adjuvant. Therefore, this paper aimed to review the role of recombinant vaccine technology, new adjuvants and the challenge of vaccine delivery. Related peer-reviewed journal article searches were conducted using a subscribed database at the Universiti Putra Malaysia library, involving areas of Health Sciences and Medicine via Medline, SCOPUS and Google Scholar. New generation vaccines include highly purified synthetic or recombinant antigens that stimulate effective cell-mediated immune and mucosal immunity. In order to enhance their efficacy, a number of adjuvants are used. Efforts have also been made to explore the usage of non-invasive routes of administration, devices and equipment for optimized antigen and immune-potentiator...
Vaccines
Peptide Vaccine: Progress and Challenges
2014 •
Weidang Li, Medha Joshi, Smita Singhania
Proceedings of the National Academy of Sciences
Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions
AN OVERVIEW OF RECOMBINANT VACCINE TECHNOLOGY, ADJUVANTS AND VACCINE DELIVERY METHODS Review Article
Shuaibu A Hudu
Human Vaccines & Immunotherapeutics
Recent progress in adjuvant discovery for peptide-based subunit vaccines
2013 •
Istvan Toth
Biotecnologia Aplicada
Development of a technological framework for using virus-like particles as adjuvants in prophylactic and therapeutic vaccines: demonstration of effect in animal models and humans
Enrique Iglesias, Julio Aguilar
Developing an effective vaccine entails: 1) proper antigenic presentation to the immune system, inducing a response of adequate intensity 2) a long duration for said response 3) the ability to steer this response towards the immune system pattern most suited for the elimination of the pathogen. Among the current crop of adjuvants, only aluminum-based gels and some oil emulsions are compliant with established regulatory and safety requirements and, not surprisingly, have received extensive use. The present work describes the development of a technological framework for the inclusion of virus-like particles (VLP) as adjuvants in vaccine preparations, allowing the induction of a functional immune response in humans that achieves seroconversion and protective antibody levels without the need for additional adjuvants. This technological framework comprises both the production and formulation of antigens as virus-like particles and the use of these VLP as adjuvants for soluble antigens, o...
Scientific Reports
A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms
2014 •
Krishna Rajan
ChemInform
ChemInform Abstract: Modern Subunit Vaccines: Development, Components, and Research Opportunities
2013 •
Istvan Toth
